The information in this section is intended for visitors outside the United States.
Gilead Sciences works to advance the care of patients suffering from life-threatening diseases around the world, including regions where access to modern medicine is limited or does not yet exist. In 2014, we significantly increased funding of these efforts, expanding the impact of more than a thousand nonprofit and NGO grantee programs around the world, including organizations in Africa, Asia, Australia, Europe, North America and South America.
The Access to Medicine Index independently ranks pharmaceutical companies’ efforts to improve access to medicine in developing countries. In 2014, it found that Gilead continues to lead in equitable intellectual property pricing and drug recall policy and practices, has increased access to its HIV-AIDS portfolio, and is a strong collaborator on improving global pharmaceutical supply chains.
Gilead significantly increased the number of grants given to nonprofit organizations through its Corporate Contributions programs in 2014. We developed deep partnerships with nonprofits around the world that work tirelessly to expand access, reduce disparity and advance education.
We believe that routine screening and expanding access to treatment may play a critical role in bringing an end to the HIV/AIDS epidemic. In the U.S., Gilead’s Frontlines of Communities in the United States (FOCUS) program works to develop effective, innovative and sustainable solutions is helping reduce the stigma associated with HIV testing.